|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
2
|
Xue C, Hu Z, Jiang W, et al: National
survey of the medical treatment status for non-small cell lung
cancer (NSCLC) in China. Lung Cancer. 77:371–375. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yarden Y: The EGFR family and its ligands
in human cancer. Signaling mechanisms and therapeutic
opportunities. Eur J Cancer. 37:S3–S8. 2001. View Article : Google Scholar
|
|
4
|
Schlessinger J: Cell signaling by receptor
tyrosine kinases. Cell. 103:211–225. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu H, Cao X, Ali-Osman F, Keir S and Lo
HW: EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial
translocalization of PUMA and PUMA-mediated apoptosis independent
of EGFR kinase activity. Cancer Lett. 294:101–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Leu CM, Chang C and Hu C: Epidermal growth
factor (EGF) suppresses staurosporine-induced apoptosis by inducing
mcl-1 via the mitogen-activated protein kinase pathway. Oncogene.
19:1665–1675. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang SH, Li Y, Chen HG, Rong J and Ye S:
Activation of proteinase-activated receptor 2 prevents apoptosis of
lung cancer cells. Cancer Invest. 31:578–581. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Q and Greene MI: EGFR enhances
survivin expression through the phosphoinositide3 (PI-3) kinase
signaling pathway. Exp Mol Pathol. 79:100–107. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Paez JG, Jänne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Woodburn JR: The epidermal growth factor
receptor and its inhibition in cancer therapy. Pharmacol Ther.
82:241–250. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wakeling AE, Guy SP, Woodburn JR, et al:
ZD1839 (Iressa): an orally active inhibitor of epidermal growth
factor signaling with potential for cancer therapy. Cancer Res.
62:5749–5754. 2002.PubMed/NCBI
|
|
13
|
Kobayashi S, Boggon TJ, Dayaram T, et al:
EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Balak MN, Gong Y, Riely GJ, et al: Novel
D761Y and common secondary T790M mutations in epidermal growth
factor receptor-mutant lung adenocarcinomas with acquired
resistance to kinase inhibitors. Clin Cancer Res. 12:6494–6501.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bean J, Brennan C, Shih JY, et al: MET
amplification occurs with or without T790M mutations in EGFR mutant
lung tumors with acquired resistance to gefitinib or erlotinib.
Proc Natl Acad Sci USA. 104:20932–20937. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Engelman JA, Zejnullahu K, Mitsudomi T, et
al: MET amplification leads to gefitinib resistance in lung cancer
by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baguley BC: Multiple drug resistance
mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liotta LA and Kohn EC: The
microenvironment of the tumor-host interface. Nature. 411:375–379.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Witz IP: Tumor-microenvironment
interactions: dangerous liaisons. Adv Cancer Res. 100:203–229.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cukierman E and Bassi DE: The mesenchymal
tumor microenvironment: a drug-resistant niche. Cell Adh Migr.
6:285–296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Flach EH, Rebecca VW, Herlyn M, Smalley KS
and Anderson AR: Fibroblasts contribute to melanoma tumor growth
and drug resistance. Mol Pharm. 8:2039–2049. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ostman A and Augsten M: Cancer-associated
fibroblasts and tumor growth - bystanders turning into key players.
Curr Opin Genet Dev. 19:67–73. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Johansson AC, Ansell A, Jerhammar F, et
al: Cancer-associated fibroblasts induce matrix
metalloproteinase-mediated cetuximab resistance in head and neck
squamous cell carcinoma cells. Mol Cancer Res. 10:1158–1168. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jansen R, Greenbaum D and Gerstein M:
Relating whole-genome expression data with protein-protein
interactions. Genome Res. 12:37–46. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sehdev V, Katsha A, Arras J, et al: HDM2
regulation by AURKA promotes cell survival in gastric cancer. Clin
Cancer Res. 20:76–86. 2014. View Article : Google Scholar :
|
|
27
|
Zimmer S, Kahl P, Buhl TM, et al:
Epidermal growth factor receptor mutations in non-small cell lung
cancer influence downstream Akt, MAPK and Stat3 signaling. J Cancer
Res Clin Oncol. 135:723–730. 2009. View Article : Google Scholar
|
|
28
|
Ostman A and Augsten M: Cancer-associated
fibroblasts and tumor growth - bystanders turning into key players.
Curr Opin Genet Dev. 19:67–73. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bhowmick NA, Neilson EG and Moses HL:
Stromal fibroblasts in cancer initiation and progression. Nature.
432:332–337. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Donev IS, Wang W, Yamada T, et al:
Transient PI3K inhibition induces apoptosis and overcomes
HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Clin Cancer Res. 17:2260–2269. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Giet R and Prigent C: Aurora/Ipl1p-related
kinases, a new oncogenic family of mitotic serine-threonine
kinases. J Cell Sci. 112:3591–3610. 1999.PubMed/NCBI
|
|
32
|
Gautschi O, Heighway J, Mack PC, Purnell
PR, Lara PN and Gandara DR: Aurora kinases as anticancer drug
targets. Clin Cancer Res. 14:1639–1648. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nishimura Y, Endo T, Kano K and Naito K:
Porcine Aurora A accelerates Cyclin B and Mos synthesis and
promotes meiotic resumption of porcine oocytes. Anim Reprod Sci.
113:114–124. 2009. View Article : Google Scholar
|
|
34
|
Anand S, Penrhyn-Lowe S and Venkitaraman
AR: Aurora-A amplification overrides the mitotic spindle assembly
checkpoint, inducing resistance to taxol. Cancer Cell. 3:51–62.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Katayama H, Sasai K, Kawai H, et al:
Phosphorylation by aurora kinase A induces Mdm2-mediated
destabilization and inhibition of p53. Nat Genet. 36:55–62. 2004.
View Article : Google Scholar : PubMed/NCBI
|
